scholarly journals Naturally Acquired Antibody Response to Malaria Transmission Blocking Vaccine Candidate Pvs230 Domain 1

2019 ◽  
Vol 10 ◽  
Author(s):  
Bergeline C. Nguemwo Tentokam ◽  
Chanaki Amaratunga ◽  
Nada A. H. Alani ◽  
Nicholas J. MacDonald ◽  
David L. Narum ◽  
...  
2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Anais Bompard ◽  
Dari F. Da ◽  
Rakiswendé S. Yerbanga ◽  
Sumi Biswas ◽  
Melissa Kapulu ◽  
...  

2001 ◽  
Vol 97 (2) ◽  
pp. 61-69 ◽  
Author(s):  
Mary Margaret G Gozar ◽  
Olga Muratova ◽  
David B Keister ◽  
Charlotte R Kensil ◽  
Virginia L Price ◽  
...  

2015 ◽  
Vol 112 (7) ◽  
pp. 1297-1305 ◽  
Author(s):  
Veronique Beiss ◽  
Holger Spiegel ◽  
Alexander Boes ◽  
Stephanie Kapelski ◽  
Matthias Scheuermayer ◽  
...  

1992 ◽  
Vol 176 (5) ◽  
pp. 1483-1487 ◽  
Author(s):  
D J Rawlings ◽  
D C Kaslow

Immune responses in major histocompatibility complex (MHC)-disparate congenic mouse strains immunized with sexual stage malaria parasites or purified recombinant protein were adjuvant dependent. Whereas mice exhibited a limited antibody response to immunization with newly emerged Plasmodium falciparum gametes in Freund's adjuvant, all five congenic mouse strains responded to several transmission-blocking vaccine candidate antigens, when parasites were emulsified in a monophosphoryl lipid A (MPL) and trehalose dimycolate (TDM) adjuvant. The humoral response in those animals immunized with the antigen in a MPL/TDM adjuvant was helper T cell dependent, as evident by boosting of the antibody response after a second immunization. If the immunogen consisted of purified recombinant protein, then the immune response was not MHC class II limited in mice immunized with either complete Freund's adjuvant or TDM/MPL. The potential role of adjuvants in overcoming apparent immune nonresponsiveness and the implications for development of a malaria transmission-blocking vaccine are discussed.


Sign in / Sign up

Export Citation Format

Share Document